PTPN11 and neuroblastoma: In this regard, pharmacological inhibition of PTPN11 in neuroblastoma cells causes RAS/MAPK pathway- and cell growth inhibition, in a manner dependent on the RAS mutational status and synergistic with RAF/MEK/ERK inhibitors (Valencia-Sama et al., 2020; Pedersen et al., 2021; Uçkun et al., 2021).